NeXstar regulatory update

NXTR's AmBisome liposomal amphotericin B received its first approval as a first-line therapy. The drug was approved in Australia as primary therapy for systemic fungal infections caused by candida, aspergillus and cryptococcus, for visceral leishmaniasis, and as a prophylaxis for liver transplantation patients at risk of developing fungal infections.

AmBisome has been approved elsewhere as second-line therapy for the treatment of life-threatening fungal infections. The company plans to apply for first-line approval in the U.S. during the first half of 1996, followed by applications in Europe. ...